articleThe Lancet OncologyAug 8, 2012Closed access

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

AMAnnika MalmströmBHBjørn Henning GrønbergCMChristine MarosiRSRoger StuppDFDidier Frappaz

County Administrative Board · Linköping University · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,265
total citations
FWCI
44.03
Percentile
100%
References
30
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Temozolomide
  • Medicine
  • Radiation therapy
  • Hazard ratio
  • Clinical endpoint
  • Randomized controlled trial
  • Glioblastoma
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding